AEON (AEON Biopharma) Ending Cash Position: $6.24 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AEON AEON Biopharma Inc AEON
10 GF Score
Price $0.24
! 2 Warning Signs
View Full Analysis

What is AEON Biopharma Ending Cash Position?

AEON Biopharma AEON -4.22% 10 Ending Cash Position is $6.24 Mil as of Mar. 2026. GuruFocus rates AEON with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

AEON Biopharma's Ending Cash Position for the quarter that ended in Mar. 2026 was $6.24 Mil.

AEON Biopharma's quarterly Ending Cash Position declined from Sep. 2025 ($5.93 Mil) to Dec. 2025 ($3.01 Mil) but then increased from Dec. 2025 ($3.01 Mil) to Mar. 2026 ($6.24 Mil).

AEON Biopharma's annual Ending Cash Position increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.01 Mil) and increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($3.01 Mil).

AEON Biopharma Ending Cash Position Related Terms

AEON Biopharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for AEON Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEON Biopharma Ending Cash Position Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 5.13 9.75 0.00 0.01 3.01

AEON Biopharma Quarterly Data
Dec19 Dec20 Jun21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.45 8.44 5.93 3.01 6.24
AEON
10GF Score
AEON Biopharma Inc AEON
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AEON Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

AEON Biopharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.013000000000001+2.993
=3.01

AEON Biopharma's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.006+3.237
=6.24

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $6.24 Mil mean?
AEON Biopharma (AEON) has a Ending Cash Position of $6.24 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on AEON Biopharma and its competitors.
Is AEON Biopharma's Ending Cash Position too high?
AEON Biopharma's current Ending Cash Position is $6.24 Mil. Overall, AEON Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does AEON Biopharma's Ending Cash Position compare to XCUR and PBM?
AEON Biopharma's Ending Cash Position of $6.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on AEON Biopharma and its competitors. AEON Biopharma's current Ending Cash Position is $6.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AEON Biopharma stock overvalued right now?
AEON Biopharma (AEON) has a current Ending Cash Position of $6.24 Mil. The current Ending Cash Position is $6.24 Mil. AEON Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For AEON Biopharma (AEON), the current Ending Cash Position is $6.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AEON Biopharma Business Description

Address 5 Park Plaza, Suite 1750, Irvine, CA, USA, 92614
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
10GF Score

Get the complete analysis for AEON

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price